Frank Volvovitz, president of MicroGeneSys

Frank Volvovitz, president of MicroGeneSys

H422/0055 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 54.1MB

Downloadable file size: 4.9MB

Price image Pricing

Please login to use the price calculator


This image is part of the feature Aids Vaccine

Credit: HANK MORGAN/SCIENCE PHOTO LIBRARY

Caption: Franklin Volvovitz, president of MicoGeneSys, a U.S. biotechnology company servicing the pharmaceuticals industry. Their product range includes VaxSyn, a trial AIDS vaccine that is based on an engineered, recombinant form of the HIV protein gp160, a precursor to an outer surface protein of the virus. VaxSyn contains no attenuated infectious parts of HIV & therefore carries no risk of transmitting AIDS. The vaccine is being developed by MicroGeneSys and is undergoing trials as a treatment of HIV- positive patients & as a potential vaccine against HIV infection.

Release details: Model release not available. Property release not required.

Keywords: developer, frank, hiv drug, portraits, surname v, vaxsyn, volvovitz

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.